Q-omics provides the consensus-scored PTPN2P2 profile across patient tissues and cancer cell-line models. PTPN2P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PTPN2P2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PTPN2P2 RNA expression shows 13,621 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where PTPN2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN2P2 survival associations across molecular data types. PTPN2P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN2P2 RNA expression–survival associations across cancer types. High PTPN2P2 expression shows unfavorable associations in UVM, ACC, LUSC and STAD, but favorable associations in LUAD and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PTPN2P2 RNA expression.
This table summarizes PTPN2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PTPN2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN2P2 shows lower tumor expression in ESCA and KIRP and higher tumor expression in KIRC, COAD, CHOL and HNSC. The KIRC box plot shows higher PTPN2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .006).
This table shows molecular features associated with PTPN2P2 in patient tissues and cancer cell lines. In patient samples, PTPN2P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
